1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Xerosis (Dry Skin) - Pipeline Review, H1 2014

Xerosis (Dry Skin) - Pipeline Review, H1 2014

  • April 2014
  • -
  • Global Markets Direct
  • -
  • 30 pages

Xerosis (Dry Skin) - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Xerosis (Dry Skin) - Pipeline Review, H1 2014’, provides an overview of the Xerosis (Dry Skin)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Xerosis (Dry Skin), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Xerosis (Dry Skin) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Xerosis (Dry Skin)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Xerosis (Dry Skin) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Xerosis (Dry Skin) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Xerosis (Dry Skin) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Xerosis (Dry Skin)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Xerosis (Dry Skin) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Xerosis (Dry Skin) - Pipeline Review, H1 2014
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Xerosis (Dry Skin) Overview 6
Therapeutics Development 7
Pipeline Products for Xerosis (Dry Skin) - Overview 7
Pipeline Products for Xerosis (Dry Skin) - Comparative Analysis 8
Xerosis (Dry Skin) - Therapeutics under Development by Companies 9
Xerosis (Dry Skin) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Xerosis (Dry Skin) - Products under Development by Companies 12
Xerosis (Dry Skin) - Companies Involved in Therapeutics Development 13
Laboratoires Pierre Fabre SA 13
Evocutis PLC 14
Foamix Ltd. 15
Xerosis (Dry Skin) - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Combination Products 17
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Drug Profiles 21
V0034-CR01B - Drug Profile 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
Emollient-1 - Drug Profile 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
Urea - Drug Profile 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
(urea + lactic acid) - Drug Profile 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
Emollient-2 - Drug Profile 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
Emollient-3 - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
Xerosis (Dry Skin) - Dormant Projects 27
Xerosis (Dry Skin) - Discontinued Products 28
Appendix 29
Methodology 29
Coverage 29
Secondary Research 29
Primary Research 29
Expert Panel Validation 29
Contact Us 30
Disclaimer 30

List of Tables

Number of Products under Development for Xerosis (Dry Skin), H1 2014 7
Number of Products under Development for Xerosis (Dry Skin) - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Late Stage Development, H1 2014 10
Comparative Analysis by Early Stage Development, H1 2014 11
Products under Development by Companies, H1 2014 12
Xerosis (Dry Skin) - Pipeline by Laboratoires Pierre Fabre SA, H1 2014 13
Xerosis (Dry Skin) - Pipeline by Evocutis PLC, H1 2014 14
Xerosis (Dry Skin) - Pipeline by Foamix Ltd., H1 2014 15
Assessment by Monotherapy Products, H1 2014 16
Assessment by Combination Products, H1 2014 17
Number of Products by Stage and Route of Administration, H1 2014 19
Number of Products by Stage and Molecule Type, H1 2014 20
Xerosis (Dry Skin) - Dormant Projects, H1 2014 27
Xerosis (Dry Skin) - Discontinued Products, H1 2014 28

List of Figures

Number of Products under Development for Xerosis (Dry Skin), H1 2014 7
Number of Products under Development for Xerosis (Dry Skin) - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Comparative Analysis by Early Stage Products, H1 2014 11
Assessment by Monotherapy Products, H1 2014 16
Number of Products by Top 10 Route of Administration, H1 2014 18
Number of Products by Stage and Top 10 Route of Administration, H1 2014 19
Number of Products by Stage and Top 10 Molecule Type, H1 2014 20

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Radiodermatitis Market: - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Radiodermatitis Market: - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • September 2016
  • by Transparency Market Research

Radiodermatitis, also known as radiation dermatitis, is a significant symptom caused by radiation therapy used in treating cancer as well as exposure to radiation during nuclear disasters. During cance ...

Phototherapy Equipment Market by Type, Application, End-user, Geography - Global Forecast to 2021

Phototherapy Equipment Market by Type, Application, End-user, Geography - Global Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global phototherapy equipment market is projected to reach USD 583.4 million by 2021, growing at a CAGR of 4.5% during the forecast period of 2016 to 2021. This market is primarily driven by the huge ...

Eczema - Market Insights, Epidemiology and Market Forecast-2023

Eczema - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Eczema - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.